ArrayExpress Uploader0mousebitransgenic Pdx1-cre/Kras*Apancreatic tumorbitransgenic Pdx1-cre/Kras*Apancreatic tumorbitransgenic Pdx1-cre/Kras*Apancreatic tumorbitransgenic Pdx1-cre/Kras*Apancreatic tumorbitransgenic Pdx1-cre/Kras*Apancreatic tumorbitransgenic Pdx1-cre/Kras*Apancreatic tumorWTpancreatic cellsWTpancreatic cellsWTpancreatic cellsWTpancreatic cellsWTpancreatic cells7532arrayexpress_sid6We have carried out transcriptional profile analysis in WT MICE and bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal...E-GEOD-53659/profile/8773/arrayexpressuploader211adenocarcinomacancerductal adenocarcinomapancreatic ductal adenocarcinomaDec.12, 2014Falseexpression-data-from-wt-mice-and-bitransgenic-pdx1E-GEOD-53659_A-AFFY-45Expression data from WT mice and bitransgenic Pdx1-cre/Kras*A mice bearing Pancreatic Ductal AdenocarcinomaNov.12, 2014We have carried out transcriptional profile analysis in WT MICE and bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal Adenocarcinoma Mouse models faithfully simulating human cancer are valuable for genetic identification of potential drug-targets but, among them, the most advantageous for practical use in subsequent preclinical testing of candidate therapeutic regimes are those exhibiting rapid tumor development. Considering that a KRAS mutation (predominantly in codon 12, such as KRASG12D; KRAS*) occurs with high frequency (~90%) in cases of human pancreatic ductal adenocarcinoma (PDA)1, we sought to develop a mouse PDA model that would exhibit high tumor incidence and short latency by ectopic overexpression of Kras*. Five WT mice and 6 bitransgenic Pdx1-cre/Kras*A MICE baring Pancreatic Ductal Adenocarcinoma were used to identify key genes in the formation of panceatic malignacieshttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-53659http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-53659/samples/